Results 141 to 150 of about 284,664 (210)
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst+5 more
wiley +1 more source
Use of artificial intelligence to assess genetic predisposition to develop critical COVID-19 disease: a comparative study of machine learning models. [PDF]
Martín Pérez S+9 more
europepmc +1 more source
ABSTRACT Mutations in the DNA polymerase epsilon (POLE) gene are associated with an increased risk of various malignancies, including colorectal and other gastrointestinal, endometrial, ovarian, breast, and brain cancers. In extremely rare cases, POLE mutations have also been associated with pancreatic and hepatobiliary carcinomas.
Lynn Messersmith+3 more
wiley +1 more source
Life's Essential 8, Genetic Susceptibility, and the Risk of Age-Related Macular Degeneration: A Prospective Cohort Study. [PDF]
Wang W+9 more
europepmc +1 more source
ABSTRACT Objective Limited research has examined the function or consequences of dietary restriction among individuals for whom it may serve differential purposes, such as those with food insecurity. Indeed, food insecurity may uniquely relate to differential functions for engaging in dietary restriction, which may relate to subsequent changes in mood;
Yvette Karvay+5 more
wiley +1 more source
Oncogenetic testing and follow-up for women with familial breast/ovarian cancer, Li-Fraumeni syndrome and Cowden syndrome [PDF]
't Kint de Roodenbeke, Daphné+10 more
core
Rhabdoid Tumor Predisposition Syndrome : A Comprehensive Review of Genetics, Clinical Manifestations, and Management. [PDF]
Kim T, Phi JH.
europepmc +1 more source
Rare germline ATM variants predispose to secondary cancer in chronic lymphocytic leukaemia patients
Cancer Communications, EarlyView.
Anna Petrackova+5 more
wiley +1 more source
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler+4 more
wiley +1 more source
Single-nucleotide human disease mutation inactivates a blood-regenerative GATA2 enhancer [PDF]
Bresnick, Emery H+12 more
core +1 more source